TheEdgeResearch
Home / Stocks / SMTI

Sanara MedTech Inc. (SMTI)

NASDAQ Healthcare Medical - Instruments & Supplies
$34.32 ▼ -0.19%
Market Cap
$315.5M
Sector
Healthcare
Industry
Medical - Instruments & Supplies
Beta
1.16
52-Wk Range
16.05-35.95
CEO
Seth D. Yon
Country
US
Currency
USD

Sanara MedTech Inc. operates in the Medical - Instruments & Supplies industry of the Healthcare sector, headquartered in Fort Worth, TX, US. The stock last traded at $34.32, down 0.19% on the session, giving a market capitalisation of $315.5M. On trailing twelve-month figures it carries a trailing P/E of -9.23, a net margin of -29.2%. Its beta of 1.16 implies it has historically moved more than the broad market.

Valuation & profitability (TTM)
P/E
-9.23
Price / Sales
2.87
Price / Book
37.42
EV / EBITDA
36.85
Gross margin
91.3%
Operating margin
9.4%
Net margin
-29.2%
Return on equity
Debt / equity
6.11
Current ratio
2.58
Dividend yield
0.0%
Payout ratio
0.0%
Company profile
Exchange
NASDAQ Capital Market
Employees
108
IPO date
1994-04-07
Headquarters
Fort Worth, TX, US
About Sanara MedTech Inc.

Sanara MedTech Inc. is a Fort Worth, Texas-based company established in 2001, dedicated to the development, marketing, and distribution of advanced wound and skin care products. These solutions are provided to a diverse clientele within the United States healthcare sector, including physicians, hospitals, clinics, and post-acute care facilities. The company's extensive product portfolio includes CellerateRX, a line of Surgical Activated Collagen in both powder and gel forms, designed to enhance patient healing across various surgical specialties. Sanara MedTech also offers a suite of Biako's antimicrobial products: a patented Skin and Wound Cleanser engineered to dismantle mature biofilm microbes by disrupting their extracellular polymeric substances, an Antimicrobial Wound Gel effective against both planktonic and biofilm-forming microbes, and an Antimicrobial Skin and Wound Irrigation Solution. Another key offering is HYCOL, a hydrolyzed Type I bovine collagen available as powder and gel, specifically formulated for the management of both full and partial thickness wounds, encompassing conditions such as pressure ulcers, venous and arterial leg ulcers, and diabetic foot ulcers. Additionally, Sanara MedTech is involved in the development of sophisticated biologic devices like FORTIFY TRG, a freeze-dried, multi-layer sheet derived from small intestinal submucosa extracellular matrix, and FORTIFY FLOWABLE extracellular matrix, an innovative wound care solution. The company also provides VIM Amnion Matrix, a single-layer amnion tissue sheet. Initially incorporated as WNDM Medical Inc., the company underwent a name change to Sanara MedTech Inc. in May 2019.

Comparable companies

Sanara MedTech Inc. is most often compared with the following Healthcare names:

HITILFMDNEOOMISGHTSTXSTBRGTRDAVMDXGN
More research on SMTI
SMTI technical analysis SMTI TheEdge Score Compare against peers
Open full interactive analysis & DCF →